CAMP Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Camp4 Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.74 |
| 52 Week High | US$12.30 |
| 52 Week Low | US$3.50 |
| Beta | 0 |
| 1 Month Change | -41.20% |
| 3 Month Change | -65.56% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.11% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CAMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.0% | -3.6% | -1.2% |
| 1Y | n/a | -8.4% | 23.2% |
Return vs Industry: Insufficient data to determine how CAMP performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CAMP performed against the US Market.
Price Volatility
| CAMP volatility | |
|---|---|
| CAMP Average Weekly Movement | 31.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CAMP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CAMP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Josh Mandel-Brehm | www.camp4tx.com |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders.
Camp4 Therapeutics Corporation Fundamentals Summary
| CAMP fundamental statistics | |
|---|---|
| Market cap | US$75.40m |
| Earnings (TTM) | -US$51.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs CAMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$37.93m |
| Gross Profit | -US$37.93m |
| Other Expenses | US$13.58m |
| Earnings | -US$51.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.0% |
How did CAMP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 19:47 |
| End of Day Share Price | 2025/01/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Camp4 Therapeutics Corporation is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Joseph | J.P. Morgan |
| Mani Foroohar | Leerink Partners LLC |
| Edward Tenthoff | Piper Sandler Companies |